The prescription of biological products is becoming increasingly
common, and these products are often the only treatment
available for certain diseases. In this article, X from Y analyses
a trend similar to that observed in the generics market. The
biotechnology industry has witnessed substantial growth in
recent times, and as it continues this trend, we are witnessing
the creation of cutting-edge manufacturing techniques
and technology for the production of these biological
products. However, due to the high level of investment in
the development of these technologies, biologics often fetch
a high market price. The high price, uneven demand, and
new advances in technology are driving the development of
biosimilars as a cheaper alternative to current biologics.
https://www.jforcs.com/7/wp-content/uploads/2016/10/Sourcing….pdf